Injectable Male Birth Control Effective for at Least 2 Years, Says Biotech Startup

Today, almost all available birth control options are female contraceptives. However, the biotech company Contraline claims that clinical studies have achieved a critical milestone for its non-hormonal and reversible male contraceptives.

In A Press release Today Contraline published that his male contraceptive called Adam was effective and safe in his first clinical study by Human in 24 months. While its clinical results still have to be published in a scientific magazine, the company plans to publish additional data during the meeting of the American Urological Association (AUA) on April 26.

Adam is a water-soluble hydrogel that has been injected into the Vasa Deferentia the two tubes in men who carry sperm from the testicles to the urethra-a small process. The implant blocks the sperm and at the same time allows ejaculation, and Contraline has marketed it as a future, long -term, reversible alternative to condoms and vasectomies.

“Our goal was to create a male contraceptive option for two years and to react directly to the needs of consumers,” said Alexander Pastuszak, Chief Medical Officer from Contaline, in the press release. “These results confirm that Adam, our new, water -soluble hydrogel, which intended lifespan can achieve.

The milestone is based on two participants in the first clinical study that Azoospermia (no sperm in its ejaculate) shows after 24 months. In A Previous press releaseCONTRAME claimed that Adam caused a reduction in the number of mobile sperm by 99.8% to 100.0% within 30 days of implantation.

These results “take us a step closer to the change in the contraceptive landscape,” said Kevin Eisenfrats, co -founder and CEO of Contraline at that time. They suggest that “it is possible to achieve a similar level of effectiveness as long-acting female contraceptives such as IUPs. In the end I would like to get Adam to become a” no-brainer “for men when it comes to taking their contraceptive options into account.” Iuds, or intrauterine devicesare small female contraceptive devices that have been inserted into the uterus.

According to the latest press release, none of the participants have registered Serious undesirable eventsOr unexpected security concerns. Researchers who carry out the clinical study will continue to monitor other participants in the 12-, 15-, 18- and 21-month markings through laboratory and home burial tests. In addition, Contraline has received full regulatory approval for the beginning of the second phase of the study.

Jon Oatley, professor at the School of Molecular Biosciences at Washington State University, pointed out that there is no public data that confirms that the Adam implant is reversible, and the researchers still don’t know the long-term effects of blocking Vasa deferentia, as he told The guardian. Oatley also suggested that most men would prefer a contraceptive pill or an operation.

However, Data from 2017 to 2019 shows that 10.4% of women between 15 and 49 years of reversible contraceptives such as IUPs or other contraceptive implants use the procedures. That is less than four points behind the 14%of the pill. If Adam really turns out to be safe and effective, a significant number of men may also choose the long -term effectiveness of an injection and not the short -term usefulness of other contraceptives.